Amyotrophic Lateral Sclerosis Market By Drug Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Amyotrophic Lateral Sclerosis Market
Amyotrophic Lateral Sclerosis Market: By Drug Type (Riluzole, Nuedexta) By Treatment Type (Stem Cell Therapy, Chemotherapy) By Distribution Partners(Hospitals, Diagnostic centres, Clinics, Retail Pharmacies) & Geography-Forecast (2016-2021)
Report Code : HCR 0115
Published: 29 January, 2016   No. of pages: 138

  • Report Description
  • Table of Contents
  • Customization Options
Amyotrophic lateral sclerosis (ALS) is a neurological disease and also termed as Lou Gehrig’s disease which results in a specific disorder that involves the death of neurons that control voluntary muscles. This is a fast progressing, invariably fatal neurological disease that attacks and damages the nerve cells (neurons) which responsible for controlling voluntary muscles. This disease is classified amongst group of disorders known as motor neuron diseases which involves gradual degeneration and death of motor neurons located in the brain, brain stem, and spinal cord. Motor Neurons acts as controlling units and vital communication links between the nervous system and the voluntary muscles of the body. Initial symptoms of this disease include fasciculation, cramps, tight and stiff muscles, muscle weakness affecting an arm or a leg, slurred and nasal speech, or difficulty chewing or swallowing which are generally overlooked or ignored.

This report identifies the global Amyotrophic lateral sclerosis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Amyotrophic lateral sclerosis market.

Amyotrophic Lateral Sclerosis Market

Globally, North America contributed the highest revenues in Amyotrophic lateral sclerosis market due high number of reported instances and deep reach of the treatments to the large number of population followed by Europe and Asia-Pacific regions as the second and third largest markets for Amyotrophic lateral sclerosis. Developing medical infrastructure in the emerging economies is expected to drive the growth of Amyotrophic lateral sclerosis market in these economies in the near future.

In this report global Amyotrophic lateral sclerosis market is further segmented based on the basis of drug type, treatment type and distribution channel partners and geography type as follows:
  • Global Amyotrophic Lateral Sclerosis  Market, By Drug Type (2014-2021): Riluzole, and Nuedexta
  • Global Amyotrophic Lateral Sclerosis  Market, By Treatment Type (2014-2021): Stem Cell Therapy, and Chemotherapy
  • Global Amyotrophic Lateral Sclerosis  Market, By Distribution Partners(2014-2021): Hospitals, Diagnostic centres, Clinics, and Retail Pharmacies
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the global Amyotrophic lateral sclerosis market. Some of the major companies’ profiles in detail are as follows:
  • GNT Pharma
  • Synthetic Biologics
  • Avicena inc
  • Amkor Pharma
  • Mitsubishi Tanabe Pharma
1. Amyotrophic Lateral Sclerosis – Market Overview
2. Executive Summary
3. 
Amyotrophic Lateral Sclerosis Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Amyotrophic Lateral Sclerosis – Market Forces
   4.1. Drivers
      4.1.1. Globally increasing incidences of anaplastic astrocytoma
   4.2. Restraints
      4.2.1. Low awareness and R&D activities in developing countries
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Amyotrophic Lateral Sclerosis  Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Global Amyotrophic Lateral Sclerosis  Market - By Drug Type 
   6.1. Riluzole
   6.2. Nuedexta
7. Global Amyotrophic Lateral Sclerosis  Market - By Treatment Type
   7.1. Stem Cell Therapy
   7.2. Chemotherapy
8. Global Amyotrophic Lateral Sclerosis  Market - By Distribution Partners
   8.1. Hospitals
   8.2. Diagnostic centres
   8.3. Clinics
   8.4. Retail Pharmacies
9. Global Amyotrophic Lateral Sclerosis  Market - By Geography 
   9.1. Europe
      9.1.1. Germany
      9.1.2. France
      9.1.3. Italy
      9.1.4. Spain
      9.1.5. Russia
      9.1.6. U.K.
      9.1.7. Rest of Europe
   9.2. Asia Pacific
      9.2.1. China
      9.2.2. India
      9.2.3. Japan
      9.2.4. South Korea
      9.2.5. Rest of Asia-Pacific
   9.3. North America
      9.3.1. U.S.
      9.3.2. Canada
      9.3.3. Mexico
   9.4. Rest of the World (RoW)
      9.4.1. Brazil
      9.4.2. Rest of RoW
10. Amyotrophic Lateral Sclerosis – Market Entropy
   10.1. Expansion
   10.2. Technological Developments
   10.3. Merger & Acquisitions, and Joint Ventures
   10.4. Supply- Contract
11. Company Profiles
   11.1. GNT Pharma
      11.1.1. Introduction
      11.1.2. Financials
      11.1.3. Key Insights
      11.1.4. Key Strategy
      11.1.5. Product Portfolio
      11.1.6. SWOT Analysis
   11.2. Synthetic Biologics
      11.2.1. Introduction
      11.2.2. Financials
      11.2.3. Key Insights
      11.2.4. Key Strategy
      11.2.5. Product Portfolio
      11.2.6. SWOT Analysis
   11.3. Avicena inc
      11.3.1.  Introduction
      11.3.2. Financials
      11.3.3. Key Insights
      11.3.4. Key Strategy
      11.3.5. Product Portfolio
      11.3.6. SWOT Analysis
   11.4. Amkor Pharma
      11.4.1. Introduction
      11.4.2. Financials
      11.4.3. Key Insights
      11.4.4. Key Strategy
      11.4.5. Product Portfolio
      11.4.6. SWOT Analysis
   11.5. Mitsubishi Tanabe Pharma
      11.5.1. Introduction
      11.5.2. Financials
      11.5.3. Key Insights
      11.5.4. Key Strategy
      11.5.5. Product Portfolio
      11.5.6. SWOT Analysis
   11.6. Sanofi 
      11.6.1. Introduction
      11.6.2. Financials
      11.6.3. Key Insights
      11.6.4. Key Strategy
      11.6.5. Product Portfolio
      11.6.6. SWOT Analysis
   11.7. Biogen Inc.
      11.7.1. Introduction
      11.7.2. Financials
      11.7.3. Key Insights
      11.7.4. Key Strategy
      11.7.5. Product Portfolio
      11.7.6. SWOT Analysis
   11.8. Apotex Corp 
      11.8.1. Introduction
      11.8.2. Financials
      11.8.3. Key Insights
      11.8.4. Key Strategy
      11.8.5. Product Portfolio
      11.8.6. SWOT Analysis
   11.9. Mylan Pharmaceuticals Inc
      11.9.1. Introduction
      11.9.2. Financials
      11.9.3. Key Insights
      11.9.4. Key Strategy
      11.9.5. Product Portfolio
      11.9.6. SWOT Analysis
   11.10. Impax Laboratories
      11.10.1.  Introduction
      11.10.2. Financials
      11.10.3. Key Insights
      11.10.4. Key Strategy
      11.10.5. Product Portfolio
      11.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports